SCHEMBL4412265

SCHEMBL4412265

N=c1oc2ccccc2cc1C(=O)[SeH]

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.61
▸ RAB9A P51151 5/20 0.61
▸ CASP3 P42574 1/20 0.61
▸ SENP7 Q9BQF6 1/20 0.61
▸ SENP6 Q9GZR1 1/20 0.61
▸ KMT2A Q03164 3/20 0.57
▸ MEN1 O00255 1/20 0.56
▸ ATM Q13315 1/20 0.56
▸ KDM4E B2RXH2 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ CA12 O43570 3/20 0.51
▸ CA9 Q16790 3/20 0.51
▸ MAOB P27338 3/20 0.51
▸ CA1 P00915 2/20 0.51
▸ CA3 P07451 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ CA4 P22748 1/20 0.51
▸ CA6 P23280 1/20 0.51
▸ CA5A P35218 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8837333 0.83 LCK (0.67) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL4412268 0.79 NPC1 (0.60) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL216822 0.76 NPC1 (1.00) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL10812793 0.76 KMT2A (0.66) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL31474878 0.76 KMT2A (0.66) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL8837282 0.73 NPC1 (0.82) NPC1RAB9ACASP3SENP7SENP6
SCHEMBL279860 0.69 MAOB (0.77) NPC1RAB9AKDM4EALDH1A1CA12
SCHEMBL29539474 0.69 MAOB (0.77) NPC1RAB9AKDM4EALDH1A1CA12
SCHEMBL34468463 0.69 MAOB (0.77) NPC1RAB9AKDM4EALDH1A1CA12
Coumarin-3-Carboxylic Acid SCHEMBL93571 0.68 MAOB (1.00) NPC1RAB9AKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635491-B2 Method for administering selenium for treating patients suffering from systemic inflammatory response syndrome (SIRS), and composition for implementing the treatment Forceville, Xavier (FR) 2009-12-22 — — US disclosed
Send feedback